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INTRODUCTION:  Inﬂammatory  myoﬁbroblastic  tumor  (IMT) is  a reactive  or inﬂammatory  state  mostly
affecting  the  pulmonary  system  and  commonly  occurs  in  children  and  young  adults.  IMT  presentation  in
the hepatic  duct  bifurcation  is  very  rare  and  has sporadically  been  reported  before.
PRESENTATION  OF  CASE:  A 12-year-old  girl  presented  with  jaundice,  pruritus  which  had  begun  5  weeks
previously.  Ultrasound  revealed  intrahepatic  biliary  ductal  dilation  and  an  isoechoic  25*30  mm  lesion
at  or near  the  conﬂuence  of the  right and  left hepatic  ducts  that  were  suggestive  of  a hilar  cholangio-
carcinoma.  Limited  resection  was  decided  intraoperatively  because  the  intraoperative  frozen  section
assessment  of the  CBD,  right  and  left  hepatic  duct  wall  samples  and  porta  hepatis  lymph  nodes  was
normal.  Histologically  the  tumor  proved  an  inﬂammatory  myoﬁbroblastic  tumor  (IMT).
DISCUSSION:  Almost  all patients  with  resectable  IMT should  be managed  with  radical  surgical  resection
or  single  nonsteroidal  anti-inﬂammatory  drugs.  In addition,  conservative  treatments  with  NSAIDs,  cor-
ticosteroids  or  chemotherapeutic  agents  could  not  be started  in many  cases  due  to the  lack of  deﬁnitive
diagnosis  of  the  mass  preoperatively.  Thus,  surgical  removal  is  frequently  unavoidable.
CONCLUSION:  Biliary  IBT  is extremely  rare  and  should  be considered  by  all hepatobiliary  surgeons  dealing
with  the  teens  with  cholangiocarcinoma,  to  avoid  unnecessary  major  surgical  resections.
© 2018  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Inﬂammatory myoﬁbroblastic tumor (IMT) is a reactive or
nﬂammatory state mostly affecting the pulmonary system and
ommonly occurs in children and young adults [1]. It includes a
pectrum of myoﬁbroblastic spindle cells proliferation along with
arying amount of inﬂammatory cell inﬁltration [2]. IMT  was ear-
ier known as inﬂammatory pseudotumor, which was  later coined
s IMT(as being a more descriptive name) by Scott et al. in 1988 [3].
MT  also can affects other organs such as the lung, liver, spleen, gas-
rointestinal tract, genitourinary tract, and heart [4]. However, its
resentation in the hepatic duct bifurcation is very rare and has
poradically been reported before. Because of its radiologic and
ehavior similarities to malignancy, IMT  can pose a notable diag-
ostic effort. A variety of diagnostic terms have been applied to this
esion previously, such as; ﬁbrous xanthoma, plasma cell granu-
oma, pseudosarcoma, lymphoid hamartoma, myxoid hamartoma,
nﬂammatory myoﬁbrohistiocytic proliferation, benign myoﬁbrob-
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latoma [5]. This work has been reported in line with the SCARE
criteria [6].
2. Case report
A 12-year-old girl presented with jaundice and pruritus which
had been begun 5 weeks previously. She also had a history of min-
imal weight loss and anorexia. Her gynaecological history was not
signiﬁcant, and her past medical and surgical history were unre-
markable. On physical examination she checked out ﬁne, except
for the presence of jaundice and scratch marks. Laboratory analysis
showed elevated total bilirubin of 19.3, direct bilirubin of 8.3 mg/dl,
Alkaline Phosphatase of 1320 U/L and Amylase of 1794 U/L. Other
routine laboratory tests were within normal limits except for a
slightly elevated aspartate aminotransferase (150 U/L) and alanine
aminotransferase (230 U/L).
Ultrasound revealed intrahepatic biliary ductal dilation and an
isoechoic 25*30 mm  lesion at or near the conﬂuence of the right and
left hepatic ducts. Common bile duct diameter (CBD) was 8 mm.
The appearances were suggestive of a hilar cholangiocarcinoma
(klatskin tumor). Spleen was 130 mm in maximum bipolar diame-
ter with normal parenchyma echo texture.
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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pFig. 1. CHD Mass (blue arrow), Dilated Intrahepatic biliary ducts (green arrow).
Abdominal helical CT conﬁrmed these ﬁndings. The mass size
as estimated 23*17 mm in CT and there were no additional patho-
ogical ﬁndings. The para-aortic and paraceliac lymph nodes were
ormal (Fig. 1).
A CA 19-9 of 493 U/ml was detected in further laboratory anal-
sis.
Subsequently, Endoscopic Retrograde cholangiopancreatogra-
hy (ERCP) was performed which revealed multiple discontinuous
tenoses in both proximal and distal part of CBD that were sug-
estive for primary sclerosing cholangitis or cholangiocarcinoma.
 biliary metallic stent was placed into the common bile duct but
ilirubin levels did not drop.
There was  no evidence of extrahepatic disease or peritoneal
eeding or lymphadenopathy on CT scan. Therefore, the patient
nderwent exploratory laparotomy with the intention of relieving
he biliary obstruction and performing a complete resection.
Surgical exploration, revealed a hard neoplastic mass in the CBD
xtending proximally towards the porta hepatis. The intraopera-
ive frozen section assessment of the CBD, right and left hepatic
uct wall specimens (three separated specimens) and porta hep-
tis lymph nodes showed no signs of malignancy. Hence, limited
epatic resection was performed. Reconstruction of the biliary
ract was performed by the end-to-end anastomosis of a normal-
ppearing intrahepatic bile duct measured 6 mm in diameter to
he remained common bile duct. The T-tube is placed in the CBD,
nchored to the abdominal wall, and joined to a closed drainage
ystem.
Histologically, the tumor proved an Inﬂammatory myoﬁbrob-
astic tumor (IMT), arising from the bile duct epithelium, composed
f monomorphic spindle cells fascicles and chronic inﬂammatory
ells including predominantly lymphocytes and few plasmacells
nd reactive mesenchymal tissues. IHC study reveal positive stain-
ng of spindle cells for SMA, Beta-cathenin and ALK and negative
eactivity for caldesmon.
The postoperative course was uneventful (excepting some
pisodes of low-grade fever). Serum bilirubin and amylase levels
ere dropped to normal limits within 20 days after the relief of the
iliary obstruction. She was discharged 21 days postoperatively.
. Discussion
Inﬂammatory myoﬁbroblastic tumor (IMT) has been classiﬁed
s tumors of intermediate biological potential by World Health
rganization (WHO) due to a tendency of local recurrence and a
ower risk of distance metastasis [6]. Various theories have been
roposed to explain the patogenesis of IMT, such as; reactivePEN  ACCESS
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etiology, infectious agents or neoplastic processes (cytogeneti-
caberrations involving the anaplastic lymphoma kinase (ALK) gene
on chromosome 2p23, which occur in approximately 50% of IMTs)
[7]. The presence of human herpesvirus-8 DNA sequences and the
over expression of interleukin 6 and cyclin D1 have been reported
in IMTs [8]. IL-6 promotes proliferation of ﬁbroblasts. Major ori-
gins of IL-6 are monocytes and macrophages which are constant
composition of IMT  [9,10]. Due to disease progression, lack of alter-
native therapeutic regimens, recurrence, almost all patients with
resectable IMT  have been managed with radical surgical resection
or single nonsteroidal anti-inﬂammatory drugs (NSAIDs) [11]. Non,
surgical management of IMT, includes anti-inﬂammatory agents
(like NSAIDs or corticosteroids) and chemotherapeutic agents (like
cyclosporine, methotrexate, azathioprine, and cyclophosphamide)
[12]. Conservative treatments with NSAIDs, corticosteroids or
chemotherapeutic agents could not be started in many cases due
to the lack of deﬁnitive diagnosis of the mass preoperatively. The
outcome of IMT  depends on its behavior which ranging from com-
pletely benign to malignant with fatal outcome [13].
In our case, IHC study reveal positive staining of SMA, ALK and
Beta-cathenin in the spindle-shaped cells.
In conclusion, biliary IMT  is extremely rare and frequently
difﬁcult to distinguish from hepatic malignant processes due to
nonspeciﬁc imaging characteristics. IMT  should be considered by
all hepatobiliary surgeons dealing with the teens with cholan-
giocarcinoma, to avoid unnecessary major surgical resections.
Percutaneous needle biopsy can be performed preoperatively for
cases of suspected IMT  to obtain a pathologic conﬁrmation and to
aid in exclusion of cholangiocarcinoma.
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